| 1. |
Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues//WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer Press, 2008: 176-178.
|
| 2. |
張艷華, 李靜, 郗彥鳳. T 淋巴母細胞白血病/淋巴瘤分子遺傳學研究進展. 白血病·淋巴瘤, 2016, 25(6): 381-384.
|
| 3. |
關偉, 靖彧, 于力. 分子遺傳學和表觀遺傳學異常在 T 淋巴母細胞淋巴瘤/白血病中的預后價值的研究進展. 中國實驗血液學雜志, 2017, 25(2): 587-591.
|
| 4. |
趙雙平, 趙銀利, 王景昌. 11 例高白細胞急性白血病死亡病例分析. 臨床醫學研究與實踐, 2019, 4(5): 150-151.
|
| 5. |
Nguyen R, Jeha S, Zhou Y, et al. The role of leukapheresis in the current management of hyperleukocytosis in newly diagnosed childhood acute lymphoblastic leukemia. Pediatr Blood Cancer, 2016, 63(9): 1546-1551.
|
| 6. |
Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J, 2017, 7(6): e577.
|
| 7. |
Kong SG, Seo JH, Jun SE, et al. Childhood acute lymphoblastic leukemia with hyperleukocytosis at presentation. Blood Res, 2014, 49(1): 29-35.
|
| 8. |
Giammarco S, Chiusolo P, Piccirillo N, et al. Hyperleukocytosis and leukostasis: management of a medical emergency. Expert Rev Hematol, 2017, 10(2): 147-154.
|
| 9. |
Brandwein JM, Zhu N, Kumar R, et al. Treatment of older patients with acute myeloid leukemia (AML): revised Canadian consensus guidelines. Am J Blood Res, 2017, 7(4): 30-40.
|
| 10. |
Chen B, Yan X, Zhang X, et al. Leukostasis retinopathy: an uncommon visual threatening complication of chronic myeloid leukemia with severe hyperleukocytosis - a case report and review of the literature. Indian J Ophthalmol, 2018, 66(12): 1871-1874.
|
| 11. |
van Dongen JJ, Langerak AW, Brüggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 concerted action BMH4-CT98-3936. Leukemia, 2003, 17(12): 2257-2317.
|
| 12. |
童春容, 王卉, 林躍輝, 等. 9 例γδT細胞淋巴瘤/白血病患者的臨床及實驗室特征. 中華血液學雜志, 2011, 32(7): 445-449.
|
| 13. |
Borel C, Dastugue N, Cances-Lauwers V, et al. PICALM-MLLT10 acute myeloid leukemia: a French cohort of 18 patients. Leuk Res, 2012, 36(11): 1365-1369.
|
| 14. |
Ben Abdelali R, Asnafi V, Petit A, et al. The prognosis of CALM-AF10-positive adult T-cell acute lymphoblastic leukemias depends on the stage of maturation arrest. Haematologica, 2013, 98(11): 1711-1717.
|
| 15. |
Stein EM, Garcia-Manero G, Rizzieri DA, et al. The DOT1L inhibitor EPZ-5676: safety and activity in relapsed/refractory patients with MLL-rearranged leukemia. Blood, 2014, 124: 387.
|
| 16. |
Bordin F, Piovan E, Masiero E, et al. WT1 loss attenuates the TP53-induced DNA damage response in T-cell acute lymphoblastic leukemia. Haematologica, 2018, 103(2): 266-277.
|
| 17. |
Stief SM, Hanneforth AL, Weser S, et al. Loss of KDM6A confers drug resistance in acute myeloid leukemia. Leukemia, 2019.
|
| 18. |
Li M, Xiao L, Xu J, et al. Co-existence of PHF6 and NOTCH1 mutations in adult T-cell acute lymphoblastic leukemia. Oncol Lett, 2016, 12(1): 16-22.
|
| 19. |
Gu Y, Han Q, McGrath M, et al. Clinical significance of novel SH2B3 mutations in adult Chinese acute lymphoblastic leukemia patients. Leuk Res, 2018, 72: 67-70.
|
| 20. |
Jenkins CE, Gusscott S, Wong RJ, et al. RUNX1 promotes cell growth in human T-cell acute lymphoblastic leukemia by transcriptional regulation of key target genes. Exp Hematol, 2018, 64: 84-96.
|
| 21. |
張弦, 張改玲, 蘇云超, 等. 西達本胺聯合化療治療復發難治性急性白血病患者 38 例. 中國新藥與臨床雜志, 2019, 38(6): 357-362.
|
| 22. |
Zelenetz AD, Wierda WG, Abramson JS, et al. Non-Hodgkin’s Lymphomas, version 3.2012. J Natl Compr Canc Netw, 2012, 10(12): 1487-1498.
|
